These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27749323)

  • 1. From the Guest Editor: The Spectrum of Treatment of Metastatic Prostate Cancer: Present and Future.
    Petrylak DP
    Cancer J; 2016; 22(5):321. PubMed ID: 27749323
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
    Dandapani SV; Wong J; Twardowski P
    Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of radium-223 in men with metastatic castration-resistant prostate cancer.
    Parker C
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):723-5. PubMed ID: 27058695
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
    George DJ
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):690-694. PubMed ID: 28949940
    [No Abstract]   [Full Text] [Related]  

  • 5. [Castration resistant prostate cancer 2015].
    Merseburger AS; Böker A; Kuczyk MA; von Klot CA
    Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies targeting castration-resistant prostate cancer.
    Gkialas IK; Fragkoulis C
    J BUON; 2015; 20(6):1389-96. PubMed ID: 26854432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 8. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.
    Dorff TB; Stein C; Kortylewski M; Posadas E; Synold T; Quinn D
    Cancer Biother Radiopharm; 2020 Sep; 35(7):485-489. PubMed ID: 32366119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):15-6. PubMed ID: 27167846
    [No Abstract]   [Full Text] [Related]  

  • 11. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment strategies in low-volume metastatic castration-resistant prostate cancer.
    Wei XX; Ko EC; Ryan CJ
    Curr Opin Urol; 2017 Nov; 27(6):596-603. PubMed ID: 28786849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in the treatment of advanced prostate cancer.
    Sternberg CN; Petrylak DP; Madan RA; Parker C
    Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
    Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):10-1. PubMed ID: 27167843
    [No Abstract]   [Full Text] [Related]  

  • 19. NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
    Umeweni N; Knight H; McVeigh G
    Lancet Oncol; 2016 Mar; 17(3):275-6. PubMed ID: 26827242
    [No Abstract]   [Full Text] [Related]  

  • 20. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.